REGENXBIO Inc. (RGNX) is a publicly traded Healthcare sector company. As of May 21, 2026, RGNX trades at $5.99 with a market cap of $292.09M and a P/E ratio of -1.04. RGNX moved +5.12% today. Year to date, RGNX is -55.45%; over the trailing twelve months it is -40.30%. Its 52-week range spans $5.04 to $16.19. Analyst consensus is strong buy with an average price target of $21.69. Rallies surfaces RGNX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes RGNX SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $5.99 |
| Market Cap | $292.09M |
| P/E Ratio | -1.04 |
| EPS | $-5.60 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.19 |
| 52-Week Low | $5.04 |
| Volume | 2.06M |
| Avg Volume | 0 |
| Revenue (TTM) | $87.82M |
| Net Income | $-290.01M |
| Gross Margin | 0.00% |
9 analysts cover RGNX: 0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $21.69.